Cloud DX Reveals EXtended Reality  Division to Bring to Market Award-Winning, Patented Metaverse Application

Cloud DX Reveals EXtended Reality Division to Bring to Market Award-Winning, Patented Metaverse Application

Cloud XR's Virtual Clinician Assistant™ offers healthcare teams an immersive and real-time augmented clinical experience, ripe for the evolving Medical Metaverse.

News in Summary

  • In its commitment to medical innovation, Cloud DX publicly unveils its Cloud XR division, after 6 years of development, to support the Medical Metaverse with its 3D holographic eXtended reality experience
  • The next iteration of this ground-breaking innovation combines the patented, award-winning VITALITI™ vital sign monitor with Microsoft's Hololens 2 or Apple's AR application along with additional integration to hospital record systems.

Cloud DX Inc. (the "Company" or "Cloud DX") (TSXV:CDX) (OTC:CDXFF), is pleased to announce the launch of its Cloud XR division as the company pursues opportunities to deliver its Virtual Clinician Assistant in an eXtended Reality platform consisting of Cloud DX's VITALITI™ continuous vital sign monitor and Connected Health software platform to render realistic 3D holographic images. This digital experience runs on Microsoft's Hololens 2 headset or through the Apple AR application. Together, this futuristic system is designed serve as a fully functioning cornerstone of the new Medical Metaverse

In October 2021, Facebook CEO Mark Zuckerberg announced that his iconic company's name would change to "Meta", an acknowledgment that the concept of the Metaverse had reached critical mass. Applications that provide real and concrete benefits in the Metaverse are gaining attention worldwide - especially those that intersect with health care.

The Cloud XR division will work with current and emerging partners to complete, test, and launch a fully 3D holographic hardware and software solution that had been in development by Cloud DX and Sheridan Center for Mobile Innovation since 2016.

This Metaverse application will allow clinicians to view 3D holographic representations of a patient's body, real-time vital sign readings, diagnostic images, and other data from their Electronic Medical Record (EMR). The Hololens 2 user interface (UI) allows clinicians to either view cutaway 3D representations of patients physically in front of them, or a patient located anywhere in the world with a 3D holographic "body" floating in space. Users can control the application with a combination of voice commands and hand gestures.

Real time data on all main vital signs are gathered by the Company's proprietary VITALITI™ continuous vital sign monitor, a patented and patent-pending system that collects heart rate, pulse rate variability, respiration, core body temperature, 5-lead ECG signals, blood oxygen saturation and most importantly, continuous non-invasive blood pressure.

The Cloud XR application is set to be integrated to a hospital's EMR system, allowing clinicians instant touch-free access to diagnostic images (x-rays, CT scans), medication records, charts, notes and other key data. Likewise, the voice command system allows doctors to dictate notes, order medications, and practice Metaverse medicine completely hands-free.

Cloud DX eXtended Reality is protected by two granted US patents, with additional patents pending in Canada, China, the European Union, and Australia.

VITALITI™ by Cloud DX has received multiple prestigious awards, including the first-ever XPRIZE Bold Epic Innovator Award, Fast Company magazine "World Changing Idea" finalist, MEDy Award for Convergence from Exponential Medicine, a 2021 Edison Award and is co-winner of the National Sciences and Engineering Research Council of Canada's 2021 Synergy Award along with Sheridan College, specifically for the eXtended Reality system.

An early iteration of the Cloud XR platform was displayed at a Singularity University event in Toronto in 2017 where it was featured in a Discovery Channel TV episode.

Applications for the eXtended Reality platform include touchless, hands-free interaction with patients vulnerable to infection, remote examination and treatment of patients by clinicians in any location, and the ability of multiple clinicians to consult on an examination of a patient from different locations. Cloud DX believes its Virtual Clinician Assistant is the most full-featured innovation currently under development for the Medical Metaverse.

"We began working with Cloud DX on the Clinic of the Future project in 2016, and together we have created a fully functioning platform with many real-life benefits for both patients and clinicians, especially as we emerge from the global pandemic," said Dr. Edward Sykes, Director, Sheridan Center for Mobile Innovation "I'm extremely excited to see Cloud DX commit to the next stage of testing and initial deployment of the VITALITI and Hololens 2 combination".

"After six years of intensive work, we are ready to show the world our cutting-edge eXtended Reality platform - at a moment in time when the delivery of services in a fully virtual Metaverse is becoming the clear direction that many technologies are heading," said Robert Kaul, CEO and Founder of Cloud DX "Once again, Cloud DX has showcased its ability to be on the forefront of innovation, with an integrated system that extends our mission to make health care better for everyone."


ABOUT Cloud DX

Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers". In 2021, Cloud DX became an exclusive partner of Medtronic Canada.

Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Links

Twitter: https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:
Janine Scott
Marketing Lead
888-543-0944
janine.scott@clouddx.com

For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@clouddx.com

SOURCE: Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/687102/Cloud-DX-Reveals-EXtended-Reality-XR-Division-to-Bring-to-Market-Award-Winning-Patented-Metaverse-Application

News Provided by ACCESSWIRE via QuoteMedia

CDX:CA
The Conversation (0)
Cloud DX partners with Sheridan College on Medical Metaverse Research and Development

Cloud DX partners with Sheridan College on Medical Metaverse Research and Development

Developing the Clinic of the Future, Cloud DX work to be supported by Sheridan College through federal grant

News in Summary

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs Contract with Paramedical Service Provider for Remote Patient Monitoring

Cloud DX Signs Contract with Paramedical Service Provider for Remote Patient Monitoring

Cloud DX chosen as Virtual Care Platform for the Ontario Paramedical Service provider, replacing existing hardware and services

Cloud DX (TSXV:CDX)(OTCQX:CDXFF) is pleased to announce a new 24-month contract with an Ontario Paramedic Service Provider enabling the client to provide Remote Patient Monitoring (RPM) across its serviceable area. Cloud DX will provide its award-winning Connected Health™ platform and support the client as it transitions from its previous remote care tools to Cloud DX's Virtual Care Platform. The client showcases how beneficial ‘Remote Care Monitoring' is for Paramedical Service providers, enabling providers to establish deeper community roots and maintain funding levels, while community members benefit from greater access to much-needed care. The client has purchased 223 Connected Health™ kits totalling ~$145,000 CAD with additional recurring fees for subscription software services. Funding for the program comes from the $82.5M Community Paramedicine for Long-Term Care program announced by the Ontario government on October 22, 2021

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs Two Contracts with US Primary Care Clinics

Cloud DX Signs Two Contracts with US Primary Care Clinics

Continued growth in US RPM as partner Maxwell Telecare signs two additional clinics in Illinois

News in Summary

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Healthcare team to use Connected Health™ kits to provide dignity in care for up to 85 patients

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Announces Closing of Private Placement

Cloud DX Announces Closing of Private Placement

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), a leading North American provider of virtual care and Remote Patient Monitoring (RPM) solutions, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 260 units (the "Units") of the Corporation at a price of $1,000 per Unit, for gross proceeds of $260,000 (the "Offering"). Each Unit is comprised of (i) a C$1,000 principal amount unsecured convertible debenture (each, a "Debenture") and (ii) 1,430 common share purchase warrants of the Corporation (each, a "Warrant"). The Debentures will mature on January 27, 2025 (the "Maturity Date") and shall bear interest at a simple rate of 10% per annum. The principal amount of the Debentures may be converted at the election of the holder thereof into common shares in the capital of the Company ("Common Shares") at a conversion price of C$0.35 per Common Share (the "Conversion Price") at any time prior to the Maturity Date. Each Warrant entitles the holder thereof to acquire one common share of the Corporation (each, a "Common Share") at a price of C$0.50 per Common Share at any time prior to 4:30 p.m. (Toronto Time) on January 27, 2024

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×